Kiniksa director exercises options, sells 6,901 shares

Kiniksa Pharmaceuticals International, plc director Barry D. Quart exercised stock options and sold the resulting shares in a planned transaction.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc director Barry D. Quart exercised stock options and sold the resulting shares in a planned transaction. On April 6, 2026, he exercised options for 6,901 Class A Ordinary Shares at $14.33 per share, then sold the same 6,901 shares at a weighted average price around $50.00 under a pre-arranged Rule 10b5-1 trading plan. His direct ownership of Class A Ordinary Shares remained at 12,546 shares after the transactions, while his remaining option position decreased by the exercised amount.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Quart Barry D

Role Director

Sold 6,901 shs ($345K)

Approx. gross sale proceeds $345K

Approx. exercise cost $99K

Type	Security	Shares	Price	Value
Exercise	Share Option	6,901	$0.00	$0.00
Exercise	Class A Ordinary Share	6,901	$14.33	$99K
Sale	Class A Ordinary Share	6,901	$50.00	$345K

Holdings After Transaction: Share Option — 26,336 contracts (Direct); Class A Ordinary Share — 12,546 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.
2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.00 and $50.015. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. F3. The option is fully vested and exercisable.

Key Figures

Options exercised: 6,901 shares Exercise price: $14.33 per share Shares sold: 6,901 shares +3 more

6 metrics

Options exercised 6,901 shares Share options exercised on April 6, 2026

Exercise price $14.33 per share Price paid to exercise options

Shares sold 6,901 shares Class A Ordinary Shares sold on April 6, 2026

Sale price range $50.00–$50.015 Prices for broker-executed trades; weighted average about $50.00

Direct shares after sale 12,546 shares Class A Ordinary Shares directly owned after transactions

Options remaining 26,336 options Share options outstanding after the derivative transaction

Key Terms

Rule 10b5-1, weighted average sales price, Class A Ordinary Shares, Share Option

4 terms

Rule 10b5-1 regulatory

"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average sales price financial

"The price reported in this column reflects a weighted average sales price"

Class A Ordinary Shares financial

"underlying_security_title: Class A Ordinary Shares"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

Share Option financial

"security_title: Share Option"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kiniksa (KNSA) director Barry D. Quart do in this Form 4 filing?

Barry D. Quart exercised options for 6,901 Class A Ordinary Shares at $14.33 and sold the same 6,901 shares around $50.00. This is an exercise-and-sell transaction rather than a fresh market purchase.

Was the KNSA insider sale by Barry D. Quart part of a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected under a Rule 10b5-1 trading plan executed on September 11, 2025. Such plans pre-schedule trades, making the timing more routine and less discretionary.

How many Kiniksa (KNSA) shares did Barry D. Quart own after these transactions?

After exercising and selling shares, Barry D. Quart directly held 12,546 Class A Ordinary Shares. His direct common share count ended unchanged because the number of shares sold matched the number of shares acquired from the option exercise.

What prices were involved in Barry D. Quart’s KNSA transactions?

He exercised options at an exercise price of $14.33 per share and sold the resulting 6,901 shares at prices ranging between $50.00 and $50.015, with a reported weighted average sales price near $50.00.

Did Barry D. Quart retain any Kiniksa stock options after this Form 4 event?

Yes. After exercising 6,901 options, the Form 4 shows 26,336 share options following the derivative transaction. The footnotes also note that the option involved was fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/08/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quart Barry D

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	04/06/2026		M(1)		6,901	A	$14.33	19,447	D
Class A Ordinary Share	04/06/2026		S(1)		6,901	D	$50(2)	12,546	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$14.33	04/06/2026		M(1)			6,901	(3)	06/28/2031	Class A Ordinary Shares	6,901	$0	26,336	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.00 and $50.015. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)